Formulary
Fluticasone with umeclidinium and vilanterol: MedNext Formulary Entry
Fluticasone with umeclidinium and vilanterol is a MedNext formulary entry. Its full entry is in the MedNext app, next to the question bank and clinical calculators.
MedNext Academy | 3 min read
Clinically reviewed by Dr Shameer Deen, MBBS, MS, MRCS
Fluticasone with umeclidinium and vilanterol: MedNext Formulary Entry
Fluticasone with umeclidinium and vilanterol is a MedNext formulary entry. Its full entry is in the MedNext app, next to the question bank and clinical calculators.
Study Fluticasone with umeclidinium and vilanterol in MedNext
The MedNext formulary entry for Fluticasone with umeclidinium and vilanterol is in the app, next to the clinical calculators and the question bank, so you can go from a drug to the questions that test it in one step.
Fluticasone with umeclidinium and vilanterol is a combination product; each component has its own entry: Fluticasone and Umeclidinium.
Clinical governance
Author: MedNext Clinical Team. Clinical reviewer: Dr Shameer Deen, MBBS, MS, MRCS. Sources: MedNext question bank. Correction: Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
FormularyFluticasone
Appears in 6 MedNext questions.
FormularyUmeclidinium
Appears in 2 MedNext questions.
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Fluticasone with umeclidinium and vilanterol in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

